Algnomics Announces Title of Oral Presentation Abstract for AACR 2026

Algnomics, a company specializing in the development of ribonucleic acid (RNA)-based gene therapies, announced on March 18 the title of the abstract scheduled for oral presentation at the American Association for Cancer Research (AACR 2026), which will be held in San Diego, USA, from April 17 to 22.

The title of the abstract is "A phase 1b/2a open-label, multicentre study of an hTERT-targeted RNA replacement gene therapy in combination with valganciclovir and anti-VEGF/PD-L1 antibodies in patients with hTERT-positive hepatocellular carcinoma." This refers to a phase 1b/2a, open-label, multicenter clinical study evaluating the efficacy of hTERT-targeted RNA replacement gene therapy combined with valganciclovir and anti-VEGF/PD-L1 antibodies in patients with hTERT-positive hepatocellular carcinoma.

The presentation on March 19 will be delivered by Professor Kim Yoonjun of the Department of Gastroenterology at Seoul National University Hospital. Algnomics plans to release interim results on the safety and efficacy of its ongoing clinical trial of RZ-001 for hepatocellular carcinoma. A company representative stated, "While the interim results of the RZ-001 clinical trial are of interest at this AACR presentation, what holds even greater significance is whether Algnomics' RNA trans-splicing technology can achieve proof-of-concept (POC) in a clinical setting. This will serve as the first major test for clinical validation of our platform technology, going beyond a single pipeline."

Meanwhile, the hepatocellular carcinoma gene therapy RZ-001 was designated as an 'Orphan Drug' by the U.S. Food and Drug Administration (FDA) in January 2024. In February of last year, it was also granted 'Fast Track' designation. Fast Track is an incentive program that allows developers and the FDA to facilitate expedited discussions during clinical development for serious conditions with inadequate existing treatment. RZ-001 is an anticancer gene therapy with a complex mechanism that targets telomerase mRNA, which is expressed in more than 80% of all cancer cell types, inducing cancer cell death, promoting immune cell infiltration, and increasing the response rate to immuno-oncology therapeutics.

This content was produced with the assistance of AI translation services.